8-K: Verastem's VS-7375 Shows Strong NSCLC Data

Verastem Oncology announced positive updated safety and efficacy data for its KRAS G12D inhibitor, VS-7375, in advanced non-small cell lung cancer from a China-based Phase 1/2 study.

Summary

• Updated safety and efficacy data for VS-7375 (GFH375 in China) from a Phase 1/2 study in advanced KRAS G12D mutant solid tumors, conducted by partner GenFleet Therapeutics, will be presented at the IASLC 2025 World Conference on Lung Cancer in September.
• The study included 142 patients, with 28 having advanced non-small cell lung cancer (NSCLC), 85 with advanced pancreatic ductal adenocarcinoma (PDAC), and 29 with other solid tumors.
• In NSCLC patients at the recommended Phase 2 dose (600 mg once daily), the overall response rate (ORR) was 68.8% (11/16) and the disease control rate (DCR) was 93.8% (15/16).
• Across all 26 evaluable NSCLC patients treated across all dose levels, the ORR was 57.7% (15/26) and DCR was 88.5% (23/26).
• Common treatment-related adverse events (TRAEs) were mostly Grade 1 or 2 in severity, with 27.5% (39/142) experiencing TRAEs and 7.7% (11/142) experiencing severe TRAEs (>Grade 3).
• No TRAE-related deaths were reported among the 142 patients in the safety population.

Sentiment

Score: 8

Explanation: The updated clinical data for VS-7375 shows a significant improvement in efficacy (ORR) and a manageable safety profile in a challenging patient population (advanced NSCLC with KRAS G12D mutation), an area with high unmet medical need. The progression to a U.S. trial and the upcoming presentation at a major conference are positive catalysts. While there are inherent risks in drug development, the current results are highly encouraging.

Positives

• High overall response rate (ORR) of 68.8% at the recommended Phase 2 dose (600 mg QD) in advanced NSCLC patients with KRAS G12D mutation.
• High disease control rate (DCR) of 93.8% at the recommended Phase 2 dose in advanced NSCLC patients.
• Significant improvement in ORR from previously reported 42% to 68.8% at the recommended dose, indicating enhanced efficacy.
• Safety profile shows most treatment-related adverse events (TRAEs) were predominately Grade 1 or 2 in severity, suggesting a manageable profile.
• Only 7.7% (11/142) of patients experienced severe TRAEs (>Grade 3).
• No TRAE-related deaths were reported.
• VS-7375 is an oral KRAS G12D (ON/OFF) inhibitor, targeting a mutation with no currently FDA-approved specific therapies, addressing a high unmet medical need.
• U.S. Investigational New Drug (IND) application for VS-7375 was cleared in April 2025, and a Phase 1/2a clinical trial was initiated in June 2025, demonstrating progress in U.S. development.

Negatives

• Treatment-related adverse events (TRAEs) occurred in 27.5% (39/142) of patients across all cancer types and dose levels.
• 11 patients required dose reduction due to TRAEs.
• 6 patients discontinued the study due to TRAEs.
• Common TRAEs included diarrhea, vomiting, nausea, anemia, decreased appetite, neutrophil count decreased, white blood cell count decreased, aspartate aminotransferase increased, asthenia, hypoalbuminemia, and alanine aminotransferase increased.

Risks

• Uncertainties inherent in research and development, such as the possibility of negative or unexpected results of clinical trials.
• No guarantee of return on investment from payments made or to be made pursuant to the collaboration and option agreement with GenFleet, or that GenFleet may fail to fully perform under the agreement.
• Development and commercialization of product candidates may take longer or cost more than planned, including as a result of conducting additional studies or decisions regarding execution of commercialization.
• Clinical data may not be available when expected.
• Preliminary and interim data may not be representative of more mature data.
• Risks related to changes in the U.S. presidential administration, including regulatory and policy changes that may adversely affect the business.
• Risks associated with potential reductions to the FDA's workforce, which may lead to disruptions and delays in the FDA's review and oversight of product candidates and impact the FDA's ability to provide timely feedback on development programs.
• Product candidates may not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients.
• Business is subject to substantial risks and uncertainties detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed March 20, 2025.

Future Outlook

The company anticipates presenting the updated VS-7375 data at the IASLC 2025 World Conference on Lung Cancer in September. It continues to support the development and potential of VS-7375 in advanced lung cancer and other advanced KRAS G12D solid tumors, with a U.S. Phase 1/2a clinical trial already initiated.

Management Comments

• "The significant increase in patients with advanced lung cancer demonstrating a response, 68.8% ORR at the recommended Phase 2 dose, and 57.7% ORR across all dose levels, is impressive and continues to support the development and potential of VS-7375 in advanced lung cancer and across other advanced KRAS G12D solid tumors."

Industry Context

The announcement highlights progress in targeting KRAS G12D mutations, which are highly prevalent in several difficult-to-treat cancers like pancreatic, colorectal, and non-small cell lung cancers. Currently, there are no FDA-approved therapies specifically targeting KRAS G12D mutations, positioning VS-7375 as a potential first-in-class or best-in-class treatment in an area of high unmet medical need. The positive efficacy data, particularly the improved ORR in NSCLC, suggests a promising development in the competitive landscape of targeted oncology therapies, especially given the high percentage of patients who had received prior systemic therapies.

Comparison to Industry Standards

• The filing states that VS-7375 is a "potential best-in-class, potent, and selective oral KRAS G12D dual ON/OFF inhibitor," implying a favorable comparison to other investigational or theoretical KRAS G12D inhibitors, though no specific comparable companies or projects are named.
• The reported ORR of 68.8% at the recommended Phase 2 dose in heavily pre-treated NSCLC patients with KRAS G12D mutation is a significant improvement over the previously reported 42% ORR from ASCO data, suggesting a strong clinical signal in a challenging patient population.
• The high disease control rate (DCR) of 93.8% at the recommended dose further supports the drug's potential in managing advanced disease.
• The safety profile, with most TRAEs being Grade 1 or 2 and no TRAE-related deaths, appears manageable, which is crucial for a drug targeting advanced cancer patients who often have compromised health.

Stakeholder Impact

• Shareholders: Positive clinical data could increase investor confidence and potentially lead to share price appreciation due to the promising development of a key pipeline asset targeting an unmet medical need.
• Patients: The positive efficacy and safety data for VS-7375 offers hope for a new treatment option for patients with advanced KRAS G12D mutant solid tumors, particularly NSCLC, where current therapies are limited.
• Employees: Continued positive clinical development supports job security and potential growth opportunities within the company.
• GenFleet Therapeutics: Reinforces the value of their collaboration with Verastem and the potential of GFH375/VS-7375.

Next Steps

• Presentation of updated data at the IASLC 2025 World Conference on Lung Cancer between September 6-9, 2025, in Barcelona, Spain.
• Continued development of VS-7375 in advanced lung cancer and other advanced KRAS G12D solid tumors.
• Ongoing Phase 1/2a clinical trial for VS-7375 in the U.S.

Key Dates

Recommendation

The updated Phase 1/2 data for VS-7375 demonstrates a significantly improved overall response rate (ORR) of 68.8% in advanced NSCLC patients with KRAS G12D mutations, a substantial increase from prior reported data. This efficacy, coupled with a manageable safety profile (predominantly Grade 1/2 TRAEs, no deaths), positions VS-7375 as a potential best-in-class therapy in an area with no FDA-approved targeted treatments. The initiation of a U.S. Phase 1/2a trial and upcoming presentation at a major oncology conference are strong catalysts. Given the high unmet medical need and the promising clinical signal, this asset significantly enhances Verastem's pipeline value, warranting a strong buy recommendation for long-term investors willing to accept clinical development risks.

Keywords

Verastem Oncology, VS-7375, GFH375, KRAS G12D, Non-Small Cell Lung Cancer, NSCLC, Oncology, Clinical Trial, Phase 1/2, GenFleet Therapeutics, Biopharmaceutical, Drug Development, Targeted Therapy, RAS/MAPK pathway